1
|
Loibl S, Weber KE, Timms KM, Elkin EP, Hahnen E, Fasching PA, Lederer B, Denkert C, Schneeweiss A, Braun S, Salat CT, Rezai M, Blohmer JU, Zahm DM, Jackisch C, Gerber B, Klare P, Kümmel S, Schem C, Paepke S, Schmutzler R, Rhiem K, Penn S, Reid J, Nekljudova V, Hartman AR, von Minckwitz G, Untch M. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto. Ann Oncol 2019; 29:2341-2347. [PMID: 30335131 DOI: 10.1093/annonc/mdy460] [Citation(s) in RCA: 155] [Impact Index Per Article: 31.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background In the neoadjuvant GeparSixto study, adding carboplatin to taxane- and anthracycline-based chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Here, we present survival data and the potential prognostic and predictive role of homologous recombination deficiency (HRD). Patients and methods Patients were randomized to paclitaxel plus nonpegylated liposomal doxorubicin (Myocet®) (PM) or PM plus carboplatin (PMCb). The secondary study end points disease-free survival (DFS) and overall survival (OS) were analyzed. Median follow-up was 47.3 months. HRD was among the exploratory analyses in GeparSixto and was successfully measured in formalin-fixed, paraffin-embedded tumor samples of 193/315 (61.3%) participants with TNBC. Homologous recombination (HR) deficiency was defined as HRD score ≥42 and/or presence of tumor BRCA mutations (tmBRCA). Results A significantly better DFS (hazard ratio 0.56, 95% CI 0.34-0.93; P = 0.022) was observed in patients with TNBC when treated with PMCb. The improvement of OS with PMCb was not statistically significant. Additional carboplatin did not improve DFS or OS in patients with HER2-positive tumors. HR deficiency was detected in 136 (70.5%) of 193 triple-negative tumors, of which 82 (60.3%) showed high HRD score without tmBRCA. HR deficiency independently predicted pCR (ypT0 ypN0) [odds ratio (OR) 2.60, 95% CI 1.26-5.37, P = 0.008]. Adding carboplatin to PM significantly increased the pCR rate from 33.9% to 63.5% in HR deficient tumors (P = 0.001), but only marginally in HR nondeficient tumors (from 20.0% to 29.6%, P = 0.540; test for interaction P = 0.327). pCR rates with carboplatin were also higher (63.2%) than without carboplatin (31.7%; OR 3.69, 1.46-9.37, P = 0.005) in patients with high HRD score but no tmBRCA. DFS rates were improved with addition of carboplatin, both in HR nondeficient (hazard ratio 0.44, 0.17-1.17, P = 0.086) and HR deficient tumors (hazard ratio 0.49, 0.23-1.04, P = 0.059). Conclusions The addition of carboplatin to neoadjuvant PM improved DFS significantly in TNBC. Long-term survival analyses support the neoadjuvant use of carboplatin in TNBC. HR deficiency in TNBC and HRD score in non-tmBRCA TNBC are predictors of response. HRD does not predict for carboplatin benefit.
Collapse
Affiliation(s)
- S Loibl
- German Breast Group, Neu-Isenburg, Germany.
| | - K E Weber
- German Breast Group, Neu-Isenburg, Germany
| | - K M Timms
- Myriad Genetics Inc, Salt Lake City, USA
| | - E P Elkin
- The Permanente Medical Group Inc, Oakland, USA
| | - E Hahnen
- Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Cologne, Germany
| | - P A Fasching
- Department of Gynecology and Obstetrics, University Hospital Erlangen, Erlangen, Germany
| | - B Lederer
- German Breast Group, Neu-Isenburg, Germany
| | - C Denkert
- Institute of Pathology, Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany
| | - A Schneeweiss
- National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany
| | - S Braun
- Brustzentrum, Sana Kliniken Offenbach, Offenbach, Germany
| | - C T Salat
- Hämatoonkologische Schwerpunktpraxis, Munich, Germany
| | - M Rezai
- Luisenkrankenhaus, Düsseldorf, Germany
| | - J U Blohmer
- Klinik für Gynäkologie mit Brustzentrum Charité, Berlin, Germany
| | - D M Zahm
- Brustzentrum SRH Waldklinikum, Gera, Germany
| | - C Jackisch
- Brustzentrum, Sana Kliniken Offenbach, Offenbach, Germany
| | - B Gerber
- Frauenklinik, Universität Rostock, Rostock, Germany
| | - P Klare
- Praxisklinik, Berlin, Germany
| | - S Kümmel
- Breast Unit, Kliniken Essen-Mitte, Essen, Germany
| | - C Schem
- Mammazentrum am Krankenhaus Jerusalem, Hamburg, Germany
| | - S Paepke
- Klinikum rechts der Isar der Technischen Universität München, Frauenklinik, München, Germany
| | - R Schmutzler
- Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Cologne, Germany
| | - K Rhiem
- Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Cologne, Germany
| | - S Penn
- Myriad Genetics Inc, Salt Lake City, USA
| | - J Reid
- Myriad Genetics Inc, Salt Lake City, USA
| | | | | | | | - M Untch
- Helios-Klinikum Berlin-Buch, Berlin, Germany
| |
Collapse
|
2
|
Lüftner D, Schuetz F, Schneeweiss A, Grischke EM, Bloch W, Decker T, Uleer C, Salat C, Förster F, Schmidt M, Mundhenke C, Tesch H, Jackisch C, Fischer T, Guderian G, Hanson S, Fasching P. Abstract P6-18-08: Everolimus + exemestane for HR+ advanced breast cancer in routine clinical practice- Final results from the non-interventional trial, BRAWO. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p6-18-08] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: In the pivotal BOLERO-2 trial, everolimus (EVE) + exemestane (EXE) more than doubled the median progression-free survival (PFS) vs EXE alone in hormone receptor positive (HR+), human epidermal growth factor-receptor 2-negative (HER2-) advanced breast cancer (ABC) recurring/progressing on/after prior non-steroidal aromatase inhibitors (NSAIs). BRAWO is a German non-interventional study conducted in patients (pts) with HR+, HER2–ABC receiving EVE + EXE, according to Summary of Product Characteristics (SmPC), in routine clinical practice. Here we report the final PFS and safety results.
Methods: This multicenter study documented 2100 pts between October 2012 and December 2017 across 341 sites in Germany. Postmenopausal women with HR+, HER2– ABC with recurrence or progression after a NSAI were included. Primary observation parameters included the evaluation of the effectiveness of EVE + EXE used in routine care for the entire pt group.
Results: In the final analysis, out of the 2100 documented pts, 2074 were included in the full analysis set. The median time since the primary diagnosis was 7.1 years and the median time from first sign of relapse (local recurrence or distant metastases) was 2.1 years. At baseline, 54.1% of pts presented with visceral metastases and 50.1% had an ECOG performance status of 0. Approximately, 63% of pts started with EVE 10 mg (median duration of exposure: 5.1 months; 95% CI, 4.6-5.4), while 34.1% started with EVE 5 mg (median duration of exposure: 4.6 months; 95% CI, 4.1-5.2).
The distribution of treatment lines was as follows: first line, 28.7% (n=595); second line, 31.9% (n=662); third line, 18.1% (n=376); fourth line, 10.7% (n=221) and, fifth line and later, 10.6% (n=220). Treatment was discontinued by 55.7% of pts (n=1170) due to progressive disease and 26% of pts (n=546) due to adverse events. The Kaplan-Meier estimate of the median PFS was 6.6 months (95% CI, 6.2-7.0). The best overall responses, based on clinical routine, were complete response, 0.8% (n=17), partial response, 7.4% (n=150), and stable disease, 41.3% (n=842). The general safety profile was consistent with the previously reported safety findings. The most common adverse events were stomatitis (any grade: 42.6%, grade 3: 3.8%, grade 4: <0.1%) and fatigue (any grade: 19.8%, grade 3: 1.5%).
Conclusions: Data from BRAWO support EVE + EXE as a suitable treatment option with a reasonable safety profile for HR+, HER2− ABC recurring or progressing on/after prior NSAIs.
Citation Format: Lüftner D, Schuetz F, Schneeweiss A, Grischke E-M, Bloch W, Decker T, Uleer C, Salat C, Förster F, Schmidt M, Mundhenke C, Tesch H, Jackisch C, Fischer T, Guderian G, Hanson S, Fasching P. Everolimus + exemestane for HR+ advanced breast cancer in routine clinical practice- Final results from the non-interventional trial, BRAWO [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P6-18-08.
Collapse
Affiliation(s)
- D Lüftner
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - F Schuetz
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - A Schneeweiss
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - E-M Grischke
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - W Bloch
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - T Decker
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - C Uleer
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - C Salat
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - F Förster
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - M Schmidt
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - C Mundhenke
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - H Tesch
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - C Jackisch
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - T Fischer
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - G Guderian
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - S Hanson
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| | - P Fasching
- Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University Hospital Heidelberg, Heidelberg, Germany; Universitäts-Frauenklinik Tubingen, Eberhard Karls University, Tubingen, Germany; German Sport University Cologne, Cologne, Germany; Studienzentrum Onkologie Ravensburg, Ravensburg, Germany; Gyn.-onkologische Gemeinschaftspraxis Hildesheim, Hildesheim, Germany; Hematology -Oncology Clinic, Munich, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Johannes Gutenberg University, Mainz, Germany; University of Kiel, Kiel, Germany; Oncological Practice Bethanien, Frankfurt, Germany; Sana Klinikum Offenbach GmbH, Offenbach, Germany; Winicker Norimed GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; Novartis Pharma GmbH, Goettingen, Germany; University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany
| |
Collapse
|
3
|
Huober J, Schneeweiss A, Blohmer JU, Denkert C, Tesch H, Hanusch CA, Salat C, Rhiem K, Rezai M, Solbach C, Fasching PA, Jackisch C, Mehta K, Nekljudova V, Seither F, von Minckwitz G, Loibl S, Untch M. Abstract P2-08-01: Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy – Results of a pooled analysis based on the GBG meta-database. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p2-08-01] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Even though patients with a pCR following neoadjuvant chemotherapy have an excellent prognosis still some of these patients will eventually relapse. A better identification of pts with an increased risk of relapse despite a pCR would be helpful to select these patients for additional post-neoadjuvant treatment strategies. Thus, the rationale of this retrospective analysis was to identify factors predicting relapse despite a pCR.
Methods
This pooled retrospective analysis based on the GBG meta-database includes the neoadjuvant trials GeparTrio, GeparQuattro, GeparQuinto, GeparSixto and GeparSepto. In these trials 2188 (27%) of 7933 pts had a pCR according to ypT0/ypTis ypN0 Definition and were included. The primary endpoint was disease-free survival (DFS), secondary endpoints were distant DFS (DDFS) and overall survival (OS). A multivariate Cox proportional hazards model was used to report hazard ratios with 95% confidence interval (CI). The two-sided significance level was set to α=0.05. Endpoints were analysed for all pts and in subgroups defined by intrinsic subtypes. The potential risk factors intrinsic subtype (HER2 negative/hormone receptor (HR) positive, triple negative, HER2 positive/HR positive, HER2 positive/HR negative), histological tumor type (lobular vs other), grade (G1/G2 vs G3), KI67 (≤20% vs higher), initial cT and cN stadium (cT1 vs cT2 vs cT3/4; cN0 vs cN+), age (≤40 vs 41-59 vs ≥60), BMI (< 25 vs 25-29 vs ≥ 30), planned number of cycles of chemotherapy (≤6 vs > 6), menopausal status (pre- vs postmenopausal) and clinical response after 2-4 cycles (SD vs PR vs CR vs PD) were included as covariates in multivariate Cox regression models as well as study identification.
Results
From 2188 evaluable patients DFS, DDFS and OS events were observed in 290/197/130 pts respectively; the median follow-up over all studies was 59 months. In multivariate analysis including study and all potential risk factors DFS was significantly different with regard to the initial cN status (cN+ vs cN0, hazard ratio (HR) 1.70; 95% CI [1.2, 2.4], p=0.002). Of borderline significance was histological type (non-lobular vs lobular, HR 0.52 95% CI [0.3, 1.1]; p=0.076) and initial tumor stage (cT3/4 vs cT1, HR 1.61 95% CI [1.0, 2.7]; p=0.064). In terms of DDFS significant differences were seen for the initial cN status (cN+ vs cN0, HR 2.34; 95% CI [1.5, 3.6], p<0.001) and initial tumor stage (cT3/4 vs cT1, HR 1.83 95% CI [1.0, 3.3]; p=0.044); histological type was again close to significance (non-lobular vs lobular, HR 0.46 95% CI [0.2, 1.1]; p=0.067). Multivariate analysis showed significantly worse OS with initial cT3/4 tumors (cT3/4 vs cT1, HR 2.48 95%CI [1.1, 5.7]; p=0.030), and the lobular type (non-lobular vs lobular, HR 0.35 95% CI [0.1, 0.9]; p=0.026) and a trend for worse OS in pts with cN+ (cN+ vs cN0, HR 1.67 95% CI [1.0, 2.9]; p=0.067).
Conclusions
Initial tumor load before start of neoadjuvant chemotherapy (tumor stage and nodal status) and lobular subtype were predictors of long term outcome after a pCR following neoadjuvant chemotherapy. Intrinsic subtype, KI67, grade and planned number of cycles were not predictive for a relapse.
Citation Format: Huober J, Schneeweiss A, Blohmer J-U, Denkert C, Tesch H, Hanusch CA, Salat C, Rhiem K, Rezai M, Solbach C, Fasching PA, Jackisch C, Mehta K, Nekljudova V, Seither F, von Minckwitz G, Loibl S, Untch M. Factors predicting relapse in early breast cancer patients with a pathological complete response after neoadjuvant therapy – Results of a pooled analysis based on the GBG meta-database [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-08-01.
Collapse
Affiliation(s)
- J Huober
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - A Schneeweiss
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - J-U Blohmer
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - C Denkert
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - H Tesch
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - CA Hanusch
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - C Salat
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - K Rhiem
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - M Rezai
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - C Solbach
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - PA Fasching
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - C Jackisch
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - K Mehta
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - V Nekljudova
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - F Seither
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - G von Minckwitz
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - S Loibl
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| | - M Untch
- Universitätsfrauenklink, Brustzentrum, Ulm, Germany; Nationales Centrum für Tumorerkrankungen, Heidelberg, Germany; Brustzentrum, Charité-Universitätsmedizin, Berlin, Germany; Institut für Pathologie, Charité-Universitätsmedizin, Berlin, Germany; Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany; Klinikum zum Roten Kreuz, München, Germany; Zentrum für Hämatologie und Onkologie, München, Germany; Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum, Köln, Germany; Medical Center, Luisenkrankenhaus, Düsseldorf, Germany; Universitätsklinikum, Frankfurt, Germany; Brustzentrum, Universitätsklinikum, Erlangen, Germany; Sana Klinikum, Offenbach, Germany; German Breast Group, Neu-Isenburg, Germany; HELIOS Klinikum, Berlin-Buch, Germany
| |
Collapse
|
4
|
Müller V, Park-Simon TW, Huober J, Schmidt M, Weide R, Reinisch M, Fehm T, Salat C, Loibl S, Mundhenke C, Winer E. A randomized study of tucatinib (ONT-380) vs. placebo in combination with capecitabine and trastuzumab in patients with pretreated HER2-pos. metastatic breast cancer: HER2CLIMB. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671504] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- V Müller
- Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie, Hamburg, Deutschland
| | - TW Park-Simon
- Medizinische Hochschule Hannover, Klinik für Frauenheilkunde und Geburtshilfe, Hannover, Deutschland
| | - J Huober
- Universitäts-Frauenklinik, Ulm, Deutschland
| | - M Schmidt
- Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Mainz, Deutschland
| | - R Weide
- Praxisklinik für Hämatologie und Onkologie, Koblenz, Deutschland
| | - M Reinisch
- Kliniken Essen Mitte, Senologie, Essen, Deutschland
| | - T Fehm
- Universitätsklinikum Düsseldorf, Frauenklinik, Düsseldorf, Deutschland
| | - C Salat
- Hope – Onkologisches Zentrum Rotkreuzklinikum, München, Deutschland
| | - S Loibl
- German Breast Group, Neu Isenburg, Deutschland
| | - C Mundhenke
- Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum SH – Campus Kiel, Kiel, Deutschland
| | - E Winer
- Dana-Farber Cancer Institute, Boston, Vereinigte Staaten von Amerika
| |
Collapse
|
5
|
Untch M, Schneeweiss A, Salat C, Rezai M, Zahm DM, Klare P, Blohmer JU, Tesch H, Khandan F, Fasching P, Jackisch C, Nekljudova V, von Minckwitz G, Loibl S. Long-term survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative (TNBC) and HER2-positive early breast cancer (GeparSixto). Ann Oncol 2017. [DOI: 10.1093/annonc/mdx362.014] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
6
|
Potthoff K, Nusch A, Söling U, Hansen R, Salat C, Grebhardt S, Harde J, Marschner N. Overall survival and quality of life in patients with metastatic breast cancer treated with nab-paclitaxel: Final results of the non-interventional study NABUCCO. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx365.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
7
|
von Minckwitz G, Timms K, Untch M, Elkin EP, Hahnen E, Fasching PA, Schneeweiss A, Salat CT, Rezai M, Blohmer JU, Zahm DM, Jackisch C, Gerber B, Klare P, Kümmel S, Paepke S, Schmutzler R, Chau S, Reid J, Hartman AR, Nekljudova V, Weber KE, Loibl S. Abstract P1-09-02: Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p1-09-02] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
Addition of carboplatin to anthracycline/taxane-based neoadjuvant chemotherapy has shown to improve pathological complete response (pCR; ypT0 ypN0) rates in patients with triple-negative breast cancer (TNBC) in two large phase II studies (GeparSixto: von Minckwitz et al, Lancet Oncol 2014, CALGB 40603: Sikov WM, J Clin Oncol 2015). Participants of the GeparSixto study showed an improvement of pCR rate from 36.9 to 53.2% (p=0.005) and DFS by absolute 9% (HR 0.56 95% CI 0.33-0.96] p=0.035) with the addition of carboplatin in the TNBC subgroup. No effect was observed in the HER2-positive subgroup. We here report results on homologous repair deficiency (HRD) status in relation to pCR and DFS in the TNBC subgroup.
Patients and Methods
In the GeparSixto trial (NCT01426880), patients were treated for 18 weeks with paclitaxel 80mg/m2 q1w and non-pegylated-liposomal doxorubicin (NPLD) 20mg/m2 q1w. Patients with TNBC (N=315) received concurrently bevacizumab 15mg/kg i.v. q2w until surgery. All patients were randomized 1:1 to receive concurrently carboplatin AUC 1.5-2 q1w vs no carboplatin. Carboplatin dose was reduced from AUC 2.0 to 1.5 by an amendment after 330 patients. Primary objective is pCR rate (ypT0 ypN0). Event free survival (EFS), and overall survival (OS) were secondary objectives. HR Deficiency status was assessed on FFPE material from pretherapeutic core biopsies. HR Deficiency was defined as either HRD score high or a BRCA mutation.
Results
HRD status was measurable in 193 of 315 TNBC patients. 101 patients of them were randomly assigned to receive carboplatin and 92 to no additional carboplatin. After median follow-up of 34.3 months 43 event free survival (EFS) events have been reported.
HR deficiency was detected in 136 (70.5%) tumors of which 79 (58.1%) showed high HRD score with intact tBRCA. HR deficiency independently predicted pCR (ypT0is ypN0) (odds ratio (OR) 2.506, CI 1.243-5.051, p=0.009). Adding carboplatin to PM significantly increased the pCR rate from 36.6% to 63.2% in HR deficient tumors with intact tBRCA (p=0.018), only marginally from 61.9% to 72.7% in BRCA mutated tumors (p=0.406), and moderately from 20.0% to 40.7% in HR non-deficient tumors (p=0.086). In general, patients with HRD deficient tumors had a better ESF than non HRD deficient ones (HR 1.805 (0.985-3.309); p=0.0526). Patients with high HRD score had an insignificant trend towards an improved EFS compared to those with low HRD score (HR 1.546 (0.764-3.127) p=0.2223). HRD deficiency did not predict carboplatin effect in patients without BRCA mutation (HR 0.8617). In multivariable analysis, only therapy, clinical nodal status before treatment, and lymphocyte predominant breast cancer were significant prognostic on EFS.
Conclusion
Within the GeparSixto study HR deficiency (either HRD score high or BRCA mutation) was associated with a higher pCR in general and an improved EFS. The effect of carboplatin could not be predicted by HR deficiency in this relatively small study. However, the results will help to understand the role of HR deficiency and the value of the HRD score in TNBC especially in patients without BRCA mutation.
Citation Format: von Minckwitz G, Timms K, Untch M, Elkin EP, Hahnen E, Fasching PA, Schneeweiss A, Salat CT, Rezai M, Blohmer J-U, Zahm D-M, Jackisch C, Gerber B, Klare P, Kümmel S, Paepke S, Schmutzler R, Chau S, Reid J, Hartman A-R, Nekljudova V, Weber KE, Loibl S. Homologous repair deficiency (HRD) as measure to predict the effect of carboplatin on survival in the neoadjuvant phase II trial GeparSixto in triple-negative early breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P1-09-02.
Collapse
Affiliation(s)
- G von Minckwitz
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - K Timms
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - M Untch
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - EP Elkin
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - E Hahnen
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - PA Fasching
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - A Schneeweiss
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - CT Salat
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - M Rezai
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - J-U Blohmer
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - D-M Zahm
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - C Jackisch
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - B Gerber
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - P Klare
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - S Kümmel
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - S Paepke
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - R Schmutzler
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - S Chau
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - J Reid
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - A-R Hartman
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - V Nekljudova
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - KE Weber
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| | - S Loibl
- German Breast Group, Neu-Isenburg, Germany; Myriad Genetic Laboratories, Salt Lake City; Helios Kliniken Berlin-Buch, Berlin, Germany; Center for Hereditary Breast and Ovarian Cancer, University Hospital Cologne, Germany; Universitätsklinikum Erlangen, Germany; Universitätsklinikum Heidelberg, Germany; Hämatologisch-Onkologische Schwerpunktpraxis Salat/Stötzer, München, Germany; Luisenkrankenhaus, Düsseldorf, Germany; Charité, Brustzentrum, Berlin, Germany; SRH Wald-Klinikum Gera, Germany; SANA Klinikum Offenbach, Germany; Universitätsfrauenklinik Rostock, Germany; Praxisklinik Krebsheilkunde für Frauen/Brustzentrum Berlin, Germany; Kliniken Essen-Mitte, Essen, Germany
| |
Collapse
|
8
|
Kurbacher C, Fietz T, Trarbach T, Salat C, Rezai M, Lorenz A, Niemeier B. Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with breast cancer: results from an interim analysis of the non-interventional study NADIR. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw390.25] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
9
|
Potthoff K, Nusch A, Söling U, Hansen R, Salat C, Grebhardt S, Marschner N. Efficacy and safety of nab-paclitaxel in patients with metastatic breast cancer: final results of the non-interventional study NABUCCO. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw365.15] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Bloch W, Baumann F, Zimmer P, Grischke EM, Fasching PA, Decker T, Uleer C, Schneeweiss A, Salat C, Wimberger P, Mundhenke C, Förster F, Kluth-Pepper B, Schubert J, Tesch H, Schütz F, Lüftner D, Jackisch C. Abstract P4-13-07: Impact of physical activity/exercise on adverse events and quality of life during treatment with everolimus and exemestane for ER+ women - Results of the 3rd interim analysis of BRAWO. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-13-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction
BRAWO is a non-interventional study collecting data of 3000 breast cancer patients treated with everolimus and exemestane (advanced or metastatic, hormone-receptor-positive, HER2-negative breast cancer). We introduce results of the 3rd preplanned interim analysis with data cut-off 08/01/ 2015, including 1300 patients. Since physical activity/exercise was reported to influence side effects as well as quality of life (QoL) of various cancer types and therapies, this analysis focuses on the impact of the physical activity/exercise history, development on adverse effects (AE) of the medical treatment and QoL.
Methods
Patients were asked to complete the EORTC QLQ-C30 QoL questionnaire and visual analogue scales (VAS-KAS) measuring their present-, past ten year- and lifetime physical activity/exercise level. To differentiate between activity/exercise levels, VAS were divided in three equal components (inactive, somewhat active, very active). Questionnaires and information about AE (e. g. stomatitis, fatigue, nausea, diarrhea, etc.) were collected before starting the medical treatment and were repeated each three months. Logistic regression model was used to estimate the impact of baseline physical activity/exercise on AE at any time point of the therapy. ANOVA models were used to calculate the impact of the baseline activity/exercise level on QoL at the last completed data set of each patient.
Results
Median age of patients was 66 years, median weight was 70 kg, median BMI was 25.9, median time since primary diagnosis was 6.2 years, and 54.4% had visceral metastases at baseline. The median PFS for the first 1300 patients was 7.1 months (95% CI, 6.5-8.0). Patients who reported to be very active (exercise) at the week prior to baseline (4.4%) showed significant lower numbers of AE compared to patients who indicate to be somewhat (14.8%) or inactive (80.8%). In contrast to the exercise level, physical activity in everyday life did not affect the AE incidence. Neither lifetime nor past ten year activity/exercise level is associated with the occurrence of AE. Regarding QoL, very active as well as somewhat active women (measured at baseline for almost each time period) showed significant higher QoL values compared to inactive women during the last assessment before death/progress.
Conclusion
Exercise prior to medical treatment with Everolimus and Exemestane may impact AE during therapy. Since physical activity did not show such a relation, this analysis highlights the importance of specific guidelines for preventive/rehabilitative exercise programs. More knowledge about dose-response relationships is needed. Furthermore a livelong healthy, "active" lifestyle may increase QoL, even in patients with advanced and terminal breast cancer disease.
Citation Format: Bloch W, Baumann F, Zimmer P, Grischke E-M, Fasching PA, Decker T, Uleer C, Schneeweiss A, Salat C, Wimberger P, Mundhenke C, Förster F, Kluth-Pepper B, Schubert J, Tesch H, Schütz F, Lüftner D, Jackisch C. Impact of physical activity/exercise on adverse events and quality of life during treatment with everolimus and exemestane for ER+ women - Results of the 3rd interim analysis of BRAWO. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-13-07.
Collapse
Affiliation(s)
- W Bloch
- University Cologne, Cologne, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; Sana Klinikum Offenbach, Offenbach, Germany
| | - F Baumann
- University Cologne, Cologne, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; Sana Klinikum Offenbach, Offenbach, Germany
| | - P Zimmer
- University Cologne, Cologne, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; Sana Klinikum Offenbach, Offenbach, Germany
| | - E-M Grischke
- University Cologne, Cologne, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; Sana Klinikum Offenbach, Offenbach, Germany
| | - PA Fasching
- University Cologne, Cologne, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; Sana Klinikum Offenbach, Offenbach, Germany
| | - T Decker
- University Cologne, Cologne, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; Sana Klinikum Offenbach, Offenbach, Germany
| | - C Uleer
- University Cologne, Cologne, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; Sana Klinikum Offenbach, Offenbach, Germany
| | - A Schneeweiss
- University Cologne, Cologne, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; Sana Klinikum Offenbach, Offenbach, Germany
| | - C Salat
- University Cologne, Cologne, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; Sana Klinikum Offenbach, Offenbach, Germany
| | - P Wimberger
- University Cologne, Cologne, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; Sana Klinikum Offenbach, Offenbach, Germany
| | - C Mundhenke
- University Cologne, Cologne, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; Sana Klinikum Offenbach, Offenbach, Germany
| | - F Förster
- University Cologne, Cologne, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; Sana Klinikum Offenbach, Offenbach, Germany
| | - B Kluth-Pepper
- University Cologne, Cologne, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; Sana Klinikum Offenbach, Offenbach, Germany
| | - J Schubert
- University Cologne, Cologne, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; Sana Klinikum Offenbach, Offenbach, Germany
| | - H Tesch
- University Cologne, Cologne, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; Sana Klinikum Offenbach, Offenbach, Germany
| | - F Schütz
- University Cologne, Cologne, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; Sana Klinikum Offenbach, Offenbach, Germany
| | - D Lüftner
- University Cologne, Cologne, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; Sana Klinikum Offenbach, Offenbach, Germany
| | - C Jackisch
- University Cologne, Cologne, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; Onkologie Bethanien, Frankfurt, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; Sana Klinikum Offenbach, Offenbach, Germany
| |
Collapse
|
11
|
Tesch H, Grischke EM, Fasching PA, Decker T, Uleer C, Schneeweiss A, Salat C, Wimberger P, Mundhenke C, Förster F, Kluth-Pepper B, Schubert J, Bloch W, Jackisch C, Schütz F, Lüftner D. Abstract P4-13-06: Results of the 3rd interim analysis of the non-interventional trial BRAWO – Subanalysis of patients <70 years and ≥ 70 years. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p4-13-06] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
BRAWO is a German non-interventional study of 3000 patients (pts) with advanced/metastatic, hormone-receptor-positive and HER2-negative breast cancer treated with everolimus and exemestane (EVE+EXE). The pivotal BOLERO-2 trial demonstrated that adding EVE to EXE improved PFS over EXE and was generally well tolerated in elderly patients with HR+ advanced breast cancer (>65 years as well as >70 years). Here we describe data of elderly patients treated with EVE+EXE in daily clinical routine.
Methods
We report data of the 3rd preplanned interim analysis (IA) of the first 1300 pts documented in BRAWO. Patient and disease characteristics in elderly patients (≥ 70 years, n=485) and patients <70 years (n=813) are described. Furthermore, safety and efficacy data for both subgroups are described.
Results
At time of data cut-off, 71% pts had discontinued the study, 29% were still ongoing. Patient and disease characteristics were comparable in both groups except for: median age (60y (range: 20-69y) vs. 75y (range 70-93y)), median time since 1st diagnosis (6.4y <70y vs. 8.8y ≥70 y), ECOG performance status 0 (56.6% <70y vs. 37.0% ≥70 y), and younger pts seemed to have less comorbidities (charlson comorbidity index (CCI)=0: 80.9% vs. 67.4%). The distribution of patients by therapy line was similar as well as tumor grading, hormone receptor status, Ki67-status and metastasis localization.
More patients in the older group received fulvestrant (20.6% vs. 16.2%), in the younger group more patients received chemotherapy (20.3% vs. 14.2%) as last antineoplastic therapy. In general, more patients in the older subgroup did not receive any chemotherapy as pretreatment (53.6% vs 40.2%).
More patients in the subgroup ≥70y received 5mg EVE as starting dose (30.3% vs. 20.8%) and had 5mg as end dose (37.9% vs. 26.9%). Median PFS was 7.1 months in the overall population, 7.0 months (6.5, 8.0; 95%CI) for pts <70y and 7.3 months (6.3, 8.6; 95%CI) for pts ≥70y. Kaplan Meier estimates for median treatment duration were longer for younger pts (167.0 days (155.0, 191.0; 95%CI vs. 128.0 days (112.0, 152.0; 95%CI)). Incidence and severity of stomatitis were comparable across subgroups (Table 1). Quality of life analysis revealed no significant differences between older and younger pts.
Table 1: Incidence and severity of stomatitis
Patient Characteristics< 70 years (n=813)≥ 70 years (n=485)Stomatitis Number of patients with at least one Stomatitis Event (based on stomatitis questionnaires)339 (41.7%)200 (41.2%)Grade 1181 (22.3%)95 (19.6%)Grade 2119 (14.6%)79 (16.3%)Grade 319 (2.3%)11 (2.3%)unknown20 (2.5%)15 (3.1%)Number of Stomatitis Events431 (100.0%)252 (100%)Grade 1237 (55.0%)125 (49.6%)Grade 2136 (31.6%)87 (34.5%)Grade 319 (4.4%)13 (5.2%)
Discussion
The data described here show that EVE+EXE treatment is effective and safe for elderly patients in daily clinical routine. This is consistent with data from an exploratory analysis of the pivotal BOLERO-2 trial, where the same differences in baseline characteristics were observed for elderly pts compared to younger pts as in BRAWO. Efficacy was also comparable to elderly pts in BOLERO-2 (mPFS 6.8 months for EVE+EXE in pts ≥70 years).
Citation Format: Tesch H, Grischke E-M, Fasching PA, Decker T, Uleer C, Schneeweiss A, Salat C, Wimberger P, Mundhenke C, Förster F, Kluth-Pepper B, Schubert J, Bloch W, Jackisch C, Schütz F, Lüftner D. Results of the 3rd interim analysis of the non-interventional trial BRAWO – Subanalysis of patients <70 years and ≥ 70 years. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P4-13-06.
Collapse
Affiliation(s)
- H Tesch
- Onkologie Bethanien, Frankfurt, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; University Cologne, Cologne, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany
| | - E-M Grischke
- Onkologie Bethanien, Frankfurt, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; University Cologne, Cologne, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany
| | - PA Fasching
- Onkologie Bethanien, Frankfurt, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; University Cologne, Cologne, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany
| | - T Decker
- Onkologie Bethanien, Frankfurt, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; University Cologne, Cologne, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany
| | - C Uleer
- Onkologie Bethanien, Frankfurt, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; University Cologne, Cologne, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany
| | - A Schneeweiss
- Onkologie Bethanien, Frankfurt, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; University Cologne, Cologne, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany
| | - C Salat
- Onkologie Bethanien, Frankfurt, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; University Cologne, Cologne, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany
| | - P Wimberger
- Onkologie Bethanien, Frankfurt, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; University Cologne, Cologne, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany
| | - C Mundhenke
- Onkologie Bethanien, Frankfurt, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; University Cologne, Cologne, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany
| | - F Förster
- Onkologie Bethanien, Frankfurt, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; University Cologne, Cologne, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany
| | - B Kluth-Pepper
- Onkologie Bethanien, Frankfurt, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; University Cologne, Cologne, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany
| | - J Schubert
- Onkologie Bethanien, Frankfurt, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; University Cologne, Cologne, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany
| | - W Bloch
- Onkologie Bethanien, Frankfurt, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; University Cologne, Cologne, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany
| | - C Jackisch
- Onkologie Bethanien, Frankfurt, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; University Cologne, Cologne, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany
| | - F Schütz
- Onkologie Bethanien, Frankfurt, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; University Cologne, Cologne, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany
| | - D Lüftner
- Onkologie Bethanien, Frankfurt, Germany; University Hospital Tuebingen, Tuebingen, Germany; University Hospital Erlangen, Erlangen, Germany; Medical Center Onkologie Ravensburg, Ravensburg, Germany; Medical Center Hildesheim, Hildesheim, Germany; National Center for Tumor Diseases, University Hospital Heidelberg, Heidelberg, Germany; Hämato-Onkologische Schwerpunktpraxis, Munich, Germany; Technical University Dresden, Dresden, Germany; University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; Poliklinik GmbH Chemnitz, Chemnitz, Germany; Novartis Pharma GmbH, Nuremberg, Germany; University Cologne, Cologne, Germany; Sana Klinikum Offenbach, Offenbach, Germany; University Hospital Heidelberg, Heidelberg, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany
| |
Collapse
|
12
|
Leyerloup S, Chabre C, Ducroz S, Germe L, Salat C, Berlie G, Chanal G, Duboeuf S, Linossier F, Trublereau P, Legrand D, Morel P, Fabrigli P. Détection bactérienne dans les concentrés de plaquettes : étude de faisabilité du système BacTx® (Immunetics). Transfus Clin Biol 2015. [DOI: 10.1016/j.tracli.2015.06.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
13
|
Issels R, Lindner L, Ghadjar P, Reichardt P, Hohenberger P, Verweij J, Abdel-Rahman S, Daugaard S, Salat C, Vujaskovic Z, Wessalowski R, Duerr H, Ploner F, Mella O, Schmidt M, Mansmann U, Jauch K, Belka C, Hiddemann W, Gronchi A. 13LBA Improved overall survival by adding regional hyperthermia to neo-adjuvant chemotherapy in patients with localized high-risk soft tissue sarcoma (HR-STS): Long-term outcomes of the EORTC 62961/ESHO randomized phase III study. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(15)30071-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
14
|
von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Gerber B, Gnauert K, Heinrich B, Prätz T, Groh U, Tanzer H, Villena C, Tulusan A, Liedtke B, Blohmer JU, Kittel K, Mau C, Potenberg J, Schilling J, Just M, Weiss E, Bückner U, Wolfgarten M, Lorenz R, Doering G, Feidicker S, Krabisch P, Deichert U, Augustin D, Kunz G, Kast K, von Minckwitz G, Nestle-Krämling C, Rezai M, Höß C, Terhaag J, Fasching P, Staib P, Aktas B, Kühn T, Khandan F, Möbus V, Solbach C, Tesch H, Stickeler E, Heinrich G, Wagner H, Abdallah A, Dewitz T, Emons G, Belau A, Rethwisch V, Lantzsch T, Thomssen C, Mattner U, Nugent A, Müller V, Noesselt T, Holms F, Müller T, Deuker JU, Schrader I, Strumberg D, Uleer C, Solomayer E, Runnebaum I, Link H, Tomé O, Ulmer HU, Conrad B, Feisel-Schwickardi G, Eidtmann H, Schumacher C, Steinmetz T, Bauerfeind I, Kremers S, Langanke D, Kullmer U, Ober A, Fischer D, Kohls A, Weikel W, Bischoff J, Freese K, Schmidt M, Wiest W, Sütterlin M, Dietrich M, Grießhammer M, Burgmann DM, Hanusch C, Rack B, Salat C, Sattler D, Tio J, von Abel E, Christensen B, Burkamp U, Köhne CH, Meinerz W, Graßhoff ST, Decker T, Overkamp F, Thalmann I, Sallmann A, Beck T, Reimer T, Bartzke G, Deryal M, Weigel M, Huober J, Weder P, Steffens CC, Lemster S, Stefek A, Ruhland F, Hofmann M, Schuster J, Simon W, Kronawitter U, Clemens M, Fehm T, Janni W, Latos K, Bauer W, Roßmann A, Bauer L, Lampe D, Heyl V, Hoffmann G, Lorenz-Salehi F, Hackmann J, Schlag R. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. Ann Oncol 2014; 25:2363-2372. [PMID: 25223482 DOI: 10.1093/annonc/mdu455] [Citation(s) in RCA: 97] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The GeparQuinto study showed that adding bevacizumab to 24 weeks of anthracycline-taxane-based neoadjuvant chemotherapy increases pathological complete response (pCR) rates overall and specifically in patients with triple-negative breast cancer (TNBC). No difference in pCR rate was observed for adding everolimus to paclitaxel in nonearly responding patients. Here, we present disease-free (DFS) and overall survival (OS) analyses. PATIENTS AND METHODS Patients (n = 1948) with HER2-negative tumors of a median tumor size of 4 cm were randomly assigned to neoadjuvant treatment with epirubicin/cyclophosphamide followed by docetaxel (EC-T) with or without eight infusions of bevacizumab every 3 weeks before surgery. Patients without clinical response to EC ± Bevacizumab were randomized to 12 weekly cycles paclitaxel with or without everolimus 5 mg/day. To detect a hazard ratio (HR) of 0.75 (α = 0.05, β = 0.8) 379 events had to be observed in the bevacizumab arms. RESULTS With a median follow-up of 3.8 years, 3-year DFS was 80.8% and 3-year OS was 89.7%. Outcome was not different for patients receiving bevacizumab (HR 1.03; P = 0.784 for DFS and HR 0.974; P = 0.842 for OS) compared with patients receiving chemotherapy alone. Patients with TNBC similarly showed no improvement in DFS (HR = 0.99; P = 0.941) and OS (HR = 1.02; P = 0.891) when treated with bevacizumab. No other predefined subgroup (HR+/HER2-; locally advanced (cT4 or cN3) or not; cT1-3 or cT4; pCR or not) showed a significant benefit. No difference in DFS (HR 0.997; P = 0.987) and OS (HR 1.11; P = 0.658) was observed for nonearly responding patients receiving paclitaxel with or without everolimus overall as well as in subgroups. CONCLUSIONS Long-term results, in opposite to the results of pCR, do not support the neoadjuvant use of bevacizumab in addition to an anthracycline-taxane-based chemotherapy or everolimus in addition to paclitaxel for nonearly responding patients. CLINICAL TRIAL NUMBER NCT 00567554, www.clinicaltrials.gov.
Collapse
Affiliation(s)
- G von Minckwitz
- Headquarter, German Breast Group, Neu-Isenburg; Department of Gynaecology and Obstetrics, University Hospital, Frankfurt.
| | - S Loibl
- Headquarter, German Breast Group, Neu-Isenburg
| | - M Untch
- Department of Gynaecology and Obstetrics, Klinikum Berlin-Buch, Berlin
| | - H Eidtmann
- Department of Gynaecology and Obstetrics, University Hospital, Kiel
| | - M Rezai
- Breast Center, Luisenkrankenhaus, Düsseldorf
| | - P A Fasching
- Department of Gynaecology and Obstetrics, University Hospital, Erlangen
| | - H Tesch
- Department of Medical Oncology, Chop GmbH, Frankfurt
| | - H Eggemann
- Department of Gynaecology and Obstetrics, University Hospital, Magdeburg
| | - I Schrader
- Department of Gynaecology and Obstetrics, Henriettenstiftung, Hannover
| | - K Kittel
- Department of Gynaecology and Obstetrics, Praxisklinik, Berlin
| | - C Hanusch
- Department of Gynaecology and Obstetrics, Rot-Kreuz-Klinikum, München
| | - J Huober
- Department of Gynaecology and Obstetrics, University Hospital, Ulm
| | - C Solbach
- Department of Gynaecology and Obstetrics, University Hospital, Frankfurt
| | - C Jackisch
- Department of Gynaecology and Obstetrics, Sana-Klinikum, Offenbach
| | - G Kunz
- Department of Gynaecology and Obstetrics, St Johannes Hospital, Dortmund
| | - J U Blohmer
- Department of Gynaecology and Obstetrics, St Gertrauden-Hospital, Berlin
| | - M Hauschild
- Department of Gynaecology and Obstetrics, Hospital, Rheinfelden
| | - T Fehm
- Department of Gynaecology and Obstetrics, University Hospital, Tübingen
| | | | - B Gerber
- Department of Gynaecology and Obstetrics, University Hospital, Rostock, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Welt A, Marschner N, Lerchenmüller C, Decker T, Salat C, Busies S, Hegewisch-Becker S. Final Efficacy and Safety Analysis of the Carin Phase III Trial: Capecitabine (Cap) and Bevacizumab (Bev) with or Without Vinorelbine (Vin) in 1St Line Metastatic Breast Cancer (Mbc). Ann Oncol 2014. [DOI: 10.1093/annonc/mdu329.9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
16
|
Welt A, Lerchenmüller C, Decker T, Marschner N, Salat C, Hegewisch-Becker S. Abstract P3-13-01: Primary efficacy endpoint analysis of the CARIN trial: Capecitabine (Cap) and bevacizumab (Bev) with or without vinorelbine (Vin) in first line metastatic breast cancer (MBC). Cancer Res 2013. [DOI: 10.1158/0008-5472.sabcs13-p3-13-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
In RIBBON-1, the combination of Bev with Cap as 1st-line therapy for MBC significantly improved progression-free survival (PFS) compared with Cap alone, with limited impact on tolerability. Vin and Cap are active agents with few overlapping toxicities. The combination of both cytotoxic drugs in phase I/II trials showed good tolerability and promising clinical activity. The CARIN trial aims to further improve efficacy by adding Vin to Cap/Bev to establish a less toxic alternative to taxane-based 1st line therapy.
Patients and Methods:
CARIN is a multicenter randomized study comparing the efficacy of Cap plus Bev versus the same regimen combined with Vin. From 04/2009 until 10/2012 598 pts in 61 participating centers were randomized (1:1) to receive Cap 1000 mg/m2 bid days 1–14 + Bev 15 mg/kg q3w (Arm A) or Cap/Bev combined with Vin 25 mg/m2 days 1+8 (Arm B). Randomization was stratified by prior therapy with anthracycline and/or taxane (yes/no) and hormone receptor status (ER/PR +/-). Treatment was continued until progression or unacceptable toxicity. Key eligibility criteria included Her-2 negative metastatic or locally recurrent disease, no prior palliative chemotherapy for MBC, ECOG ≤2, and absence of brain metastases. Primary endpoint was progression-free survival (PFS); secondary endpoints included objective response rate, overall survival, and safety & tolerability. Baseline demographics, prior therapy and disease characteristics were well balanced. 21.5% of pts had triple negative BC, 10.6% had bone metastases only. Progression free survival data for the two treatment arms will be compared using a log-rank test. The influence of pretreatment, hormone receptor status and predictive variables on progression free survival will be analyzed within a cox regression model.
Results:
Data Cleaning and analysis will be complete by October 2013 and results for the primary endpoint PFS and secondary endpoints will be presented at the meeting.
Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P3-13-01.
Collapse
Affiliation(s)
- A Welt
- West German Cancer Center, University Hospital, Essen, Germany; Onkologische Schwerpunktpraxis, Münster, Germany; Onkologische Schwerpunktpraxis, Ravensburg, Germany; Onkologische Schwerpunktpraxis, Freiburg, Germany; Onkologische Schwerpunktpraxis, München, Germany; Onkologische Schwerpunktpraxis, Hamburg, Germany
| | - C Lerchenmüller
- West German Cancer Center, University Hospital, Essen, Germany; Onkologische Schwerpunktpraxis, Münster, Germany; Onkologische Schwerpunktpraxis, Ravensburg, Germany; Onkologische Schwerpunktpraxis, Freiburg, Germany; Onkologische Schwerpunktpraxis, München, Germany; Onkologische Schwerpunktpraxis, Hamburg, Germany
| | - T Decker
- West German Cancer Center, University Hospital, Essen, Germany; Onkologische Schwerpunktpraxis, Münster, Germany; Onkologische Schwerpunktpraxis, Ravensburg, Germany; Onkologische Schwerpunktpraxis, Freiburg, Germany; Onkologische Schwerpunktpraxis, München, Germany; Onkologische Schwerpunktpraxis, Hamburg, Germany
| | - N Marschner
- West German Cancer Center, University Hospital, Essen, Germany; Onkologische Schwerpunktpraxis, Münster, Germany; Onkologische Schwerpunktpraxis, Ravensburg, Germany; Onkologische Schwerpunktpraxis, Freiburg, Germany; Onkologische Schwerpunktpraxis, München, Germany; Onkologische Schwerpunktpraxis, Hamburg, Germany
| | - C Salat
- West German Cancer Center, University Hospital, Essen, Germany; Onkologische Schwerpunktpraxis, Münster, Germany; Onkologische Schwerpunktpraxis, Ravensburg, Germany; Onkologische Schwerpunktpraxis, Freiburg, Germany; Onkologische Schwerpunktpraxis, München, Germany; Onkologische Schwerpunktpraxis, Hamburg, Germany
| | - S Hegewisch-Becker
- West German Cancer Center, University Hospital, Essen, Germany; Onkologische Schwerpunktpraxis, Münster, Germany; Onkologische Schwerpunktpraxis, Ravensburg, Germany; Onkologische Schwerpunktpraxis, Freiburg, Germany; Onkologische Schwerpunktpraxis, München, Germany; Onkologische Schwerpunktpraxis, Hamburg, Germany
| |
Collapse
|
17
|
Farr A, Wuerstlein R, Neff J, Issels R, Lindner L, Belka C, Lauber K, Rauch J, Scheithauer H, Salat C, Pastorekova S, Takacova M, Friese K, Harbeck N. Identifikation von prädiktiven Biomarkern für Hyperthermie und Re-Bestrahlung beim loko-regionären Rezidiv des Mammakarzinoms. Geburtshilfe Frauenheilkd 2013. [DOI: 10.1055/s-0033-1347878] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
18
|
Janni W, Sarosiek T, Pikiel J, Karaszewska B, Staroslawska E, Salat C, Caglevic C, Potemski P, Brain E, Briggs K, de Silvio M, Sapunar F, Papadimitriou C. Abstract P5-18-21: A Phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC). Cancer Res 2012. [DOI: 10.1158/0008-5472.sabcs12-p5-18-21] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Lapatinib (L), a dual kinase inhibitor of epidermal growth factor receptor and ErbB2, is effective in the treatment of ErbB2+ MBC in combination with capecitabine (C) following progression after trastuzumab, anthracyclines, and taxanes. Vinorelbine (V) is an important chemotherapy option in MBC, and multiple Phase II trials have been conducted in combination with trastuzumab. This randomized, open-label, multicenter, Phase II study (LAP112620, VITAL) evaluated the efficacy and safety of L with either V or C in women with ErbB2+ MBC.
Methods: Patients with MBC who had received ≤1 chemotherapy regimen in the metastatic setting were randomized 2:1 to either L 1250 mg orally once daily (QD) continuously plus V 20 mg/m2 intravenously on Days 1 and 8, every third week, or L 1250 mg orally QD continuously plus C 2000 mg/m2/day orally in 2 doses 12 hours apart on Days 1–14 every third week. Patients were stratified by prior receipt of therapy for MBC (Y/N) and site of metastatic disease (visceral/soft tissue or bone-only). The primary endpoint of progression-free survival (PFS) was assessed once all subjects had been followed for a minimum of 6 months or had otherwise progressed, died or withdrawn, if sooner. The primary focus was to evaluate PFS in the L plus V arm with a descriptive intent only. Other endpoints included overall response rate, overall survival, and safety. Patients progressing on one treatment arm were given the option of crossing over to the other arm.
Results: 112 patients were randomized. The results and conclusions sections will be updated once the primary analysis has been completed in September 2012.
ClinicalTrials.gov - NCT01013740
Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-18-21.
Collapse
Affiliation(s)
- W Janni
- Klinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; Centrum Medyczne Ostrobramska, NZOZ Magodent, Warsaw, Poland; Wojewodzkie Centrum Onkologii, Centrum Badan Klinicznych, Gdansk, Poland; Przychodnia Lekarska NZOZ “KOMED”, Konin, Poland; Centrum Onkologii Ziemii Lubelskiej, Lublin, Poland; Hämato-Onkologische Gemeinschaftspraxis, München, Germany; Mariano Sanchez Fontecilla, Las Condes, Chile; Wojewodzki Szpital Specjalistyczny, Kopernika, Poland; Institut Curie - Hôpital René Huguenin, Saint-Cloud, France; GlaxoSmithKline Oncology, Uxbridge, Middlesex, United Kingdom; GlaxoSmithKline Oncology, Collegeville, PA; Therapeutic Clinic, General Hospital of Athens, Greece
| | - T Sarosiek
- Klinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; Centrum Medyczne Ostrobramska, NZOZ Magodent, Warsaw, Poland; Wojewodzkie Centrum Onkologii, Centrum Badan Klinicznych, Gdansk, Poland; Przychodnia Lekarska NZOZ “KOMED”, Konin, Poland; Centrum Onkologii Ziemii Lubelskiej, Lublin, Poland; Hämato-Onkologische Gemeinschaftspraxis, München, Germany; Mariano Sanchez Fontecilla, Las Condes, Chile; Wojewodzki Szpital Specjalistyczny, Kopernika, Poland; Institut Curie - Hôpital René Huguenin, Saint-Cloud, France; GlaxoSmithKline Oncology, Uxbridge, Middlesex, United Kingdom; GlaxoSmithKline Oncology, Collegeville, PA; Therapeutic Clinic, General Hospital of Athens, Greece
| | - J Pikiel
- Klinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; Centrum Medyczne Ostrobramska, NZOZ Magodent, Warsaw, Poland; Wojewodzkie Centrum Onkologii, Centrum Badan Klinicznych, Gdansk, Poland; Przychodnia Lekarska NZOZ “KOMED”, Konin, Poland; Centrum Onkologii Ziemii Lubelskiej, Lublin, Poland; Hämato-Onkologische Gemeinschaftspraxis, München, Germany; Mariano Sanchez Fontecilla, Las Condes, Chile; Wojewodzki Szpital Specjalistyczny, Kopernika, Poland; Institut Curie - Hôpital René Huguenin, Saint-Cloud, France; GlaxoSmithKline Oncology, Uxbridge, Middlesex, United Kingdom; GlaxoSmithKline Oncology, Collegeville, PA; Therapeutic Clinic, General Hospital of Athens, Greece
| | - B Karaszewska
- Klinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; Centrum Medyczne Ostrobramska, NZOZ Magodent, Warsaw, Poland; Wojewodzkie Centrum Onkologii, Centrum Badan Klinicznych, Gdansk, Poland; Przychodnia Lekarska NZOZ “KOMED”, Konin, Poland; Centrum Onkologii Ziemii Lubelskiej, Lublin, Poland; Hämato-Onkologische Gemeinschaftspraxis, München, Germany; Mariano Sanchez Fontecilla, Las Condes, Chile; Wojewodzki Szpital Specjalistyczny, Kopernika, Poland; Institut Curie - Hôpital René Huguenin, Saint-Cloud, France; GlaxoSmithKline Oncology, Uxbridge, Middlesex, United Kingdom; GlaxoSmithKline Oncology, Collegeville, PA; Therapeutic Clinic, General Hospital of Athens, Greece
| | - E Staroslawska
- Klinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; Centrum Medyczne Ostrobramska, NZOZ Magodent, Warsaw, Poland; Wojewodzkie Centrum Onkologii, Centrum Badan Klinicznych, Gdansk, Poland; Przychodnia Lekarska NZOZ “KOMED”, Konin, Poland; Centrum Onkologii Ziemii Lubelskiej, Lublin, Poland; Hämato-Onkologische Gemeinschaftspraxis, München, Germany; Mariano Sanchez Fontecilla, Las Condes, Chile; Wojewodzki Szpital Specjalistyczny, Kopernika, Poland; Institut Curie - Hôpital René Huguenin, Saint-Cloud, France; GlaxoSmithKline Oncology, Uxbridge, Middlesex, United Kingdom; GlaxoSmithKline Oncology, Collegeville, PA; Therapeutic Clinic, General Hospital of Athens, Greece
| | - C Salat
- Klinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; Centrum Medyczne Ostrobramska, NZOZ Magodent, Warsaw, Poland; Wojewodzkie Centrum Onkologii, Centrum Badan Klinicznych, Gdansk, Poland; Przychodnia Lekarska NZOZ “KOMED”, Konin, Poland; Centrum Onkologii Ziemii Lubelskiej, Lublin, Poland; Hämato-Onkologische Gemeinschaftspraxis, München, Germany; Mariano Sanchez Fontecilla, Las Condes, Chile; Wojewodzki Szpital Specjalistyczny, Kopernika, Poland; Institut Curie - Hôpital René Huguenin, Saint-Cloud, France; GlaxoSmithKline Oncology, Uxbridge, Middlesex, United Kingdom; GlaxoSmithKline Oncology, Collegeville, PA; Therapeutic Clinic, General Hospital of Athens, Greece
| | - C Caglevic
- Klinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; Centrum Medyczne Ostrobramska, NZOZ Magodent, Warsaw, Poland; Wojewodzkie Centrum Onkologii, Centrum Badan Klinicznych, Gdansk, Poland; Przychodnia Lekarska NZOZ “KOMED”, Konin, Poland; Centrum Onkologii Ziemii Lubelskiej, Lublin, Poland; Hämato-Onkologische Gemeinschaftspraxis, München, Germany; Mariano Sanchez Fontecilla, Las Condes, Chile; Wojewodzki Szpital Specjalistyczny, Kopernika, Poland; Institut Curie - Hôpital René Huguenin, Saint-Cloud, France; GlaxoSmithKline Oncology, Uxbridge, Middlesex, United Kingdom; GlaxoSmithKline Oncology, Collegeville, PA; Therapeutic Clinic, General Hospital of Athens, Greece
| | - P Potemski
- Klinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; Centrum Medyczne Ostrobramska, NZOZ Magodent, Warsaw, Poland; Wojewodzkie Centrum Onkologii, Centrum Badan Klinicznych, Gdansk, Poland; Przychodnia Lekarska NZOZ “KOMED”, Konin, Poland; Centrum Onkologii Ziemii Lubelskiej, Lublin, Poland; Hämato-Onkologische Gemeinschaftspraxis, München, Germany; Mariano Sanchez Fontecilla, Las Condes, Chile; Wojewodzki Szpital Specjalistyczny, Kopernika, Poland; Institut Curie - Hôpital René Huguenin, Saint-Cloud, France; GlaxoSmithKline Oncology, Uxbridge, Middlesex, United Kingdom; GlaxoSmithKline Oncology, Collegeville, PA; Therapeutic Clinic, General Hospital of Athens, Greece
| | - E Brain
- Klinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; Centrum Medyczne Ostrobramska, NZOZ Magodent, Warsaw, Poland; Wojewodzkie Centrum Onkologii, Centrum Badan Klinicznych, Gdansk, Poland; Przychodnia Lekarska NZOZ “KOMED”, Konin, Poland; Centrum Onkologii Ziemii Lubelskiej, Lublin, Poland; Hämato-Onkologische Gemeinschaftspraxis, München, Germany; Mariano Sanchez Fontecilla, Las Condes, Chile; Wojewodzki Szpital Specjalistyczny, Kopernika, Poland; Institut Curie - Hôpital René Huguenin, Saint-Cloud, France; GlaxoSmithKline Oncology, Uxbridge, Middlesex, United Kingdom; GlaxoSmithKline Oncology, Collegeville, PA; Therapeutic Clinic, General Hospital of Athens, Greece
| | - K Briggs
- Klinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; Centrum Medyczne Ostrobramska, NZOZ Magodent, Warsaw, Poland; Wojewodzkie Centrum Onkologii, Centrum Badan Klinicznych, Gdansk, Poland; Przychodnia Lekarska NZOZ “KOMED”, Konin, Poland; Centrum Onkologii Ziemii Lubelskiej, Lublin, Poland; Hämato-Onkologische Gemeinschaftspraxis, München, Germany; Mariano Sanchez Fontecilla, Las Condes, Chile; Wojewodzki Szpital Specjalistyczny, Kopernika, Poland; Institut Curie - Hôpital René Huguenin, Saint-Cloud, France; GlaxoSmithKline Oncology, Uxbridge, Middlesex, United Kingdom; GlaxoSmithKline Oncology, Collegeville, PA; Therapeutic Clinic, General Hospital of Athens, Greece
| | - M de Silvio
- Klinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; Centrum Medyczne Ostrobramska, NZOZ Magodent, Warsaw, Poland; Wojewodzkie Centrum Onkologii, Centrum Badan Klinicznych, Gdansk, Poland; Przychodnia Lekarska NZOZ “KOMED”, Konin, Poland; Centrum Onkologii Ziemii Lubelskiej, Lublin, Poland; Hämato-Onkologische Gemeinschaftspraxis, München, Germany; Mariano Sanchez Fontecilla, Las Condes, Chile; Wojewodzki Szpital Specjalistyczny, Kopernika, Poland; Institut Curie - Hôpital René Huguenin, Saint-Cloud, France; GlaxoSmithKline Oncology, Uxbridge, Middlesex, United Kingdom; GlaxoSmithKline Oncology, Collegeville, PA; Therapeutic Clinic, General Hospital of Athens, Greece
| | - F Sapunar
- Klinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; Centrum Medyczne Ostrobramska, NZOZ Magodent, Warsaw, Poland; Wojewodzkie Centrum Onkologii, Centrum Badan Klinicznych, Gdansk, Poland; Przychodnia Lekarska NZOZ “KOMED”, Konin, Poland; Centrum Onkologii Ziemii Lubelskiej, Lublin, Poland; Hämato-Onkologische Gemeinschaftspraxis, München, Germany; Mariano Sanchez Fontecilla, Las Condes, Chile; Wojewodzki Szpital Specjalistyczny, Kopernika, Poland; Institut Curie - Hôpital René Huguenin, Saint-Cloud, France; GlaxoSmithKline Oncology, Uxbridge, Middlesex, United Kingdom; GlaxoSmithKline Oncology, Collegeville, PA; Therapeutic Clinic, General Hospital of Athens, Greece
| | - C Papadimitriou
- Klinikum der Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany; Centrum Medyczne Ostrobramska, NZOZ Magodent, Warsaw, Poland; Wojewodzkie Centrum Onkologii, Centrum Badan Klinicznych, Gdansk, Poland; Przychodnia Lekarska NZOZ “KOMED”, Konin, Poland; Centrum Onkologii Ziemii Lubelskiej, Lublin, Poland; Hämato-Onkologische Gemeinschaftspraxis, München, Germany; Mariano Sanchez Fontecilla, Las Condes, Chile; Wojewodzki Szpital Specjalistyczny, Kopernika, Poland; Institut Curie - Hôpital René Huguenin, Saint-Cloud, France; GlaxoSmithKline Oncology, Uxbridge, Middlesex, United Kingdom; GlaxoSmithKline Oncology, Collegeville, PA; Therapeutic Clinic, General Hospital of Athens, Greece
| |
Collapse
|
19
|
Lordick F, Sehouli J, Vergote I, Rosenberg P, Schneeweiss A, Block A, Salat C, Scambia G, Berton-Rigaud D, Wimberger P. Maintenance of Quality of Life in Patients with Malignant Ascites During Treatment with the Trifunctional Antibody Catumaxomab: Results from the Phase III B Casimas Trial. Ann Oncol 2012. [DOI: 10.1016/s0923-7534(20)34144-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
|
20
|
Untch M, von Minckwitz G, Konecny G, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Beckmann M, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Nekljudova V, Lebeau A, Loibl S, Fasching P. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin–cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer—outcome on prognosis. Ann Oncol 2011; 22:1999-2006. [DOI: 10.1093/annonc/mdq713] [Citation(s) in RCA: 87] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Untch M, Fasching P, Konecny G, von Koch F, Conrad U, Fett W, Kurzeder C, Lück HJ, Stickeler E, Urbaczyk H, Liedtke B, Salat C, Harbeck N, Müller V, Schmidt M, Hasmüller S, Lenhard M, Schuster T, Nekljudova V, Lebeau A, Loibl S, von Minckwitz G. PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primary breast cancer—results at the time of surgery. Ann Oncol 2011; 22:1988-1998. [DOI: 10.1093/annonc/mdq709] [Citation(s) in RCA: 97] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Tschoep-Lechner K, Dieterle N, Abdel-Rahman S, Lindner L, Salat C, Ehrke S, Weber B, Bruns CJ, Heinemann V, Mansmann U, Issels RD. Regional hyperthermia (RHT) as an innovative treatment component: RHT combined with gemcitabine (G) and cisplatin (CIS) in G-pretreated advanced pancreatic cancer (APC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e14524] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
23
|
Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, Neumeister P, Finazzi G, Iacobelli M, Bowyer K, Prentice HG, Barbui T. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2008. [DOI: 10.1111/j.1365-2141.2000.02475.x] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
24
|
Tschoep KE, Boeck S, Berger F, Maier V, Abdel-Rahman S, Kuhlencordt M, Salat C, Schmidt M, Heinemann V, Issels RD. Regional hyperthermia (RHT) combined with gemcitabine (GEM) + cisplatin (CIS) in patients with GEM-refractory advanced pancreatic cancer: Results of the ESHO phase II trial. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4635] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Tschoep KE, Milani V, Schmidt G, Schiel X, Abdel-Rahman S, Kuhlencordt MF, Salat C, Maier V, Heinemann V, Issels RD. Gemcitabine + cisplatin (GEM+CIS) in combination with regional hyperthermia (RHT) in second-line therapy of gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.14073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14073 Background: Our completed phase III trial comparing GEM + CIS vs. GEM alone showed good efficacy for the combination arm in 1st-line therapy (ASCO abstr. No. 1003, 2003). Based on the rationale of chemosensitization of CIS by RHT we are performing a prospective phase II study with GEM + CIS combined with RHT. Methods: Until 8/2005 12 pts with metastatic pancreatic adenocarcinoma who failed GEM-based 1st-line-therapy were enrolled in this study. One cycle consisted of GEM (1000mg/m2) on d1 followed by CIS (25mg/m2) on d2 and d4 combined with RHT (BSD system). A total of 2 blocks each of 4 cycles were given biweekly. The main endpoints were time to second progression (TTP2) and 1-year event free survival (1-yr-EFS). TTP2 and EFS were defined as time from start of 2nd-line therapy until progression of disease or death. Response (RECIST) was evaluated after 4 and 8 cycles of therapy. Results: Pt characteristics: median age 60; M:F=8:4. Median time to first progression (TTP1) was 6 months (95% CI:2–7). 8/12 pts received all 8 cycles. No toxic death and no grade 4 toxicity occurred. In 12/2005 10/12 pts were evaluable for this study. Control of disease (1CR, 2MR, 4NC) and progression (3PD) occurred in 70% and 30% respectively. The median TTP2 is 8 months (95% CI: 2–13) and the 1-yr-EFS is 32% (95% CI:3–61). 7 pts are alive at 12/2005. Conclusions: Our ongoing study (EudraCT-No 2005–003855–11) using RHT combined with GEM + CIS shows promising antitumor activity with a very encouraging TTP2 and median 1-yr-EFS in the 2nd-line treatment of GEM-refractory metastatic pancreatic cancer. [Table: see text]
Collapse
Affiliation(s)
- K. E. Tschoep
- University of Munich, Munich, Germany; Interne Klinik Dr. Argirov, Kempfenhausen, Berg, Germany; Rotkreuz-Krankenhaus, Munich, Germany; Medical Clinic III, University of Munich and GSF, Munich, Germany
| | - V. Milani
- University of Munich, Munich, Germany; Interne Klinik Dr. Argirov, Kempfenhausen, Berg, Germany; Rotkreuz-Krankenhaus, Munich, Germany; Medical Clinic III, University of Munich and GSF, Munich, Germany
| | - G. Schmidt
- University of Munich, Munich, Germany; Interne Klinik Dr. Argirov, Kempfenhausen, Berg, Germany; Rotkreuz-Krankenhaus, Munich, Germany; Medical Clinic III, University of Munich and GSF, Munich, Germany
| | - X. Schiel
- University of Munich, Munich, Germany; Interne Klinik Dr. Argirov, Kempfenhausen, Berg, Germany; Rotkreuz-Krankenhaus, Munich, Germany; Medical Clinic III, University of Munich and GSF, Munich, Germany
| | - S. Abdel-Rahman
- University of Munich, Munich, Germany; Interne Klinik Dr. Argirov, Kempfenhausen, Berg, Germany; Rotkreuz-Krankenhaus, Munich, Germany; Medical Clinic III, University of Munich and GSF, Munich, Germany
| | - M. F. Kuhlencordt
- University of Munich, Munich, Germany; Interne Klinik Dr. Argirov, Kempfenhausen, Berg, Germany; Rotkreuz-Krankenhaus, Munich, Germany; Medical Clinic III, University of Munich and GSF, Munich, Germany
| | - C. Salat
- University of Munich, Munich, Germany; Interne Klinik Dr. Argirov, Kempfenhausen, Berg, Germany; Rotkreuz-Krankenhaus, Munich, Germany; Medical Clinic III, University of Munich and GSF, Munich, Germany
| | - V. Maier
- University of Munich, Munich, Germany; Interne Klinik Dr. Argirov, Kempfenhausen, Berg, Germany; Rotkreuz-Krankenhaus, Munich, Germany; Medical Clinic III, University of Munich and GSF, Munich, Germany
| | - V. Heinemann
- University of Munich, Munich, Germany; Interne Klinik Dr. Argirov, Kempfenhausen, Berg, Germany; Rotkreuz-Krankenhaus, Munich, Germany; Medical Clinic III, University of Munich and GSF, Munich, Germany
| | - R. D. Issels
- University of Munich, Munich, Germany; Interne Klinik Dr. Argirov, Kempfenhausen, Berg, Germany; Rotkreuz-Krankenhaus, Munich, Germany; Medical Clinic III, University of Munich and GSF, Munich, Germany
| |
Collapse
|
26
|
Stemmler HJ, Menzel H, Salat C, Lindhofer H, Kahlert S, Heinemann V, Kolb HJ. Lasting remission following multimodal treatment in a patient with metastatic breast cancer. Anticancer Drugs 2006; 16:1135-7. [PMID: 16222157 DOI: 10.1097/01.cad.0000180122.24031.13] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
We report on a lasting remission from multimodal treatment in a patient with hepatic metastasized breast cancer. After surgical removal of a singular hepatic metastasis, the patient underwent leukapheresis of peripheral blood mononuclear cell (PBMCs). For induction chemotherapy, the patient received 2 cycles of epirubicin and paclitaxel (ET). After 1 cycle of epirubicin and ifosfamide (EI), peripheral blood stem cells were harvested. After a final cycle of ET, the patient underwent high-dose chemotherapy (HDCT; thiotepa 600 mg/m/melphalan 180 mg/m) and autologous stem cell transplantation. Once reconstitution was achieved, PBMCs were reinfused followed by i.v. application of a trifunctional antibody (TrAb) with specificities anti-EpCAMxanti-CD3. TrAbs are able to simultaneously bind tumor cells, T cells, and additionally FcgammaR type I and III+accessory cells via their Fc region. Side-effects during treatment were hematotoxicity, mucositis and gastrointestinal toxicity. TrAb treatment resulted in intermittent fever, chills, elevated liver enzymes, systemic inflammatory response syndrome and pulmonary leakage. With a follow-up period of more than 8 years the patient is still in remission (96+months). This case suggests the feasibility and efficacy of combining surgery, standard and HDCT, and subsequent immunotherapy in metastatic breast cancer. Further investigation of this approach is indicated in a subgroup of patients with oligometastatic breast cancer.
Collapse
Affiliation(s)
- H J Stemmler
- Department of Hematology/Oncology, Klinikum Grosshadern, University of Munich, Munich, Germany.
| | | | | | | | | | | | | |
Collapse
|
27
|
Pihusch M, Wegner H, Goehring P, Salat C, Pihusch V, Andreesen R, Kolb HJ, Holler E, Pihusch R. Protein C and procollagen III peptide levels in patients with hepatic dysfunction after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2005; 36:631-7. [PMID: 16062176 DOI: 10.1038/sj.bmt.1705114] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Veno-occlusive disease (VOD) is one of the most serious complications following hematopoietic stem cell transplantation (HSCT) and is associated with a high mortality. We conducted a large trial on the clinical significance of protein C (PC) and procollagen III peptide (PNPIII) levels, which have been described as possible diagnostic markers of VOD. In total, 350 patients undergoing allogeneic HSCT were included. PC and PNPIII levels were analyzed prior to conditioning and weekly until 8 weeks after the HSCT. Signs of VOD and other transplantation-related complications (graft-versus-host disease (GVHD), toxicity, microangiopathic hemolytic anemia, infection) were recorded weekly throughout the trial. Patients showed a significant drop of the PC levels in VOD (70.3 vs 96.3%, P<0.001) and with increasing severity of aGVHD. Steroids increased the PC levels (69.4% vs 109.4%, P<0.001). The highest PNPIII levels were registered in patients with VOD (mean 6.3 IU/ml). Patients with aGVHD showed an elevation of PNPIII, especially patients with hepatic aGVHD. PC levels during conditioning do not predict VOD (98.5 vs 76.5%, NS). Although PC and PNPIII may play a role in the pathogenesis of VOD they cannot discriminate between complications with jaundice and are only of limited help in the differential diagnosis of VOD.
Collapse
Affiliation(s)
- M Pihusch
- Abteilung fuer Haematologie und Internistische Onkologie, Klinikum der Universitaet Regensburg, Regensburg, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
28
|
Stemmler HJ, Salat C, Lindhofer H, Menzel H, Untch M, Kahlert S, Konecny G, Sauer H, Ledderose G, Heinemann V, Kolb HJ. Combined treatment of metastatic breast cancer (MBC) by high-dose chemotherapy (HDCT) and bispecific antibodies: a pilot study. Anticancer Res 2005; 25:3047-54. [PMID: 16080564] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
UNLABELLED This pilot study analyzed the efficacy and toxicity of high-dose chemotherapy (HDCT), autologous stem-cell transplantation (ASCT) and subsequent immunotherapy with T-cell reinfusion and trifunctional antibodies (trAbs) in chemotherapy-sensitive patients with metastatic breast cancer (MBC). PATIENTS AND METHODS After leukapheresis and cryopreservation of T-cells, patients received 2 cycles of induction chemotherapy ET (epirubicin/paclitaxel) and 1 cycle of El (epirubicin/ifosfamide), followed by G-CSF and stem-cell harvest. After a final cycle of ET, responders (CR/PR) underwent HDCT (thiotepa 600 mg/m2/melphalan 140-180 mg/m2) and ASCT. Once reconstitution was achieved, T-cells were reinfused, followed by application of trifunctional antibodies with specificities anti-EpCAM X anti-CD3 and anti-Her2/neu X anti-CD3. RESULTS Thirty-three patients were recruited into the study and 19, who had responded to initial chemotherapy, underwent HDCT and ASCT (4 CR, 15 PR, OR = 57.6%; 95% CI: 40-75%). Two early deaths were observed (1 toxic, 1 early progression). T-cell reinfusion and trAbs were given to 17 patients. TrAbs treatment resulted in intermittent fever, chills and elevated liver enzymes, which were seen in all patients. The median overall survival was 27.7 months (range: 5.9-82.6+). Patients who received 3 trAbs doses showed a trend towards an improved overall survival (47.2 vs. 22.4 months, p = 0.08 log rank). CONCLUSION This pilot study has shown the feasibility of combining HDCT with immunotherapy in MBC. Further investigation of this approach is indicated.
Collapse
Affiliation(s)
- H J Stemmler
- Department of Hematology-Oncology, University of Munich, Germany.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Schlemmer M, Wendtner CM, Falk M, Lindner LH, Abdel-Rahman S, Salat C, Hiddemann W, Issels RD. Efficacy of consolidation high-dose chemotherapy (HDCT) with ifosfamide, carboplatin and etoposide followed by peripheral blood stem cell rescue (PBSCR) in chemosensitive patients with metastatic soft tissue sarcomas. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | - M. Falk
- Klinikum Grosshadern, Muenchen, Germany
| | | | | | - C. Salat
- Klinikum Grosshadern, Muenchen, Germany
| | | | | |
Collapse
|
30
|
Stemmler HJ, Salat C, Lindhofer H, Menzel M, Sauer H, Untch M, Konecny G, Ledderose G, Kolb HJ, Heinemann V. High dose chemotherapy (HDCT) and hematopoietic stem cell transplantation (HPSCT) with subsequent immunotherapy in metastatic breast cancer (MBC): Final results of a phase I stud. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- H. J. Stemmler
- University of Munich, Dept of Oncology, Munich, Germany; Medical Onology, Munich, Germany; Trion Pharma, Munich, Germany; University of Technology, Dept of Oncology, Munich, Germany; University of Munich, Dept of Gynecology, Munich, Germany
| | - C. Salat
- University of Munich, Dept of Oncology, Munich, Germany; Medical Onology, Munich, Germany; Trion Pharma, Munich, Germany; University of Technology, Dept of Oncology, Munich, Germany; University of Munich, Dept of Gynecology, Munich, Germany
| | - H. Lindhofer
- University of Munich, Dept of Oncology, Munich, Germany; Medical Onology, Munich, Germany; Trion Pharma, Munich, Germany; University of Technology, Dept of Oncology, Munich, Germany; University of Munich, Dept of Gynecology, Munich, Germany
| | - M. Menzel
- University of Munich, Dept of Oncology, Munich, Germany; Medical Onology, Munich, Germany; Trion Pharma, Munich, Germany; University of Technology, Dept of Oncology, Munich, Germany; University of Munich, Dept of Gynecology, Munich, Germany
| | - H. Sauer
- University of Munich, Dept of Oncology, Munich, Germany; Medical Onology, Munich, Germany; Trion Pharma, Munich, Germany; University of Technology, Dept of Oncology, Munich, Germany; University of Munich, Dept of Gynecology, Munich, Germany
| | - M. Untch
- University of Munich, Dept of Oncology, Munich, Germany; Medical Onology, Munich, Germany; Trion Pharma, Munich, Germany; University of Technology, Dept of Oncology, Munich, Germany; University of Munich, Dept of Gynecology, Munich, Germany
| | - G. Konecny
- University of Munich, Dept of Oncology, Munich, Germany; Medical Onology, Munich, Germany; Trion Pharma, Munich, Germany; University of Technology, Dept of Oncology, Munich, Germany; University of Munich, Dept of Gynecology, Munich, Germany
| | - G. Ledderose
- University of Munich, Dept of Oncology, Munich, Germany; Medical Onology, Munich, Germany; Trion Pharma, Munich, Germany; University of Technology, Dept of Oncology, Munich, Germany; University of Munich, Dept of Gynecology, Munich, Germany
| | - H. J. Kolb
- University of Munich, Dept of Oncology, Munich, Germany; Medical Onology, Munich, Germany; Trion Pharma, Munich, Germany; University of Technology, Dept of Oncology, Munich, Germany; University of Munich, Dept of Gynecology, Munich, Germany
| | - V. Heinemann
- University of Munich, Dept of Oncology, Munich, Germany; Medical Onology, Munich, Germany; Trion Pharma, Munich, Germany; University of Technology, Dept of Oncology, Munich, Germany; University of Munich, Dept of Gynecology, Munich, Germany
| |
Collapse
|
31
|
Hentrich M, Stoetzer OJ, Salat C, Ledderose G. [Chronic myeloid leukemia--case report]. Dtsch Med Wochenschr 2002; 127:2617. [PMID: 12469273 DOI: 10.1055/s-2002-35924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- M Hentrich
- Krankenhaus München-Harlaching, VI. Medizinische Abteilung, Germany
| | | | | | | |
Collapse
|
32
|
Stoetzer OJ, Hentrich M, Salat C. [Chronic myeloid leukemia--treatment]. Dtsch Med Wochenschr 2002; 127:2621-4. [PMID: 12469275 DOI: 10.1055/s-2002-35948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- O J Stoetzer
- Hämato-Onkologische Schwerpunktpraxis am Rotkreuzplatz, München, Germany.
| | | | | |
Collapse
|
33
|
Stoetzer OJ, Hentrich M, Salat C. [Chronic myeloid leukemia--pathophysiology and diagnosis]. Dtsch Med Wochenschr 2002; 127:2618-20. [PMID: 12469274 DOI: 10.1055/s-2002-35947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
MESH Headings
- Bone Marrow/pathology
- Diagnosis, Differential
- Female
- Fusion Proteins, bcr-abl/analysis
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/etiology
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics
- Leukocyte Count
- Male
- Philadelphia Chromosome
- Prognosis
- Risk Factors
Collapse
Affiliation(s)
- O J Stoetzer
- Hämato-Onkologische Schwerpunktpraxis am Rotkreuzplatz, München, Germany.
| | | | | |
Collapse
|
34
|
Pihusch R, Wegner H, Salat C, Pihusch M, Holler E, Kolb HJ, Hiller E. Flow cytometric findings in platelets of patients following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 30:381-7. [PMID: 12235523 DOI: 10.1038/sj.bmt.1703663] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2002] [Accepted: 05/29/2002] [Indexed: 11/09/2022]
Abstract
Following allogeneic hematopoietic stem cell transplantation (HSCT) patients may have an increased bleeding tendency in spite of a normal platelet count. Moreover, an association between chronic graft-versus-host disease (cGVHD) and a thrombophilic state has been observed. Platelet receptors and granules from 27 patients following HSCT (13 without cGVHD, 14 with cGVHD) were evaluated by flow cytometric analysis and compared to 62 healthy controls. Platelets from HSCT patients stained weakly with mepacrine indicating a reduced content of dense bodies, whereas no significant degranulation reaction of alpha granules and lysosomes was detectable. In addition, a lower surface expression of GP Ia/IIa was observed, indicating an acquired thrombocytopathy. The surface receptors are activated in HSCT patients, which could be seen by the lower surface expression of GP Ib internalized during the activation process and elevated levels of LIBS-1 and PAC-1 antibody binding. Patients with cGVHD had a seven-fold increased ratio of microparticles. This study demonstrates platelet receptor and granule defects in patients following HSCT. The key role of platelets in HSCT-associated hemostatic disorders is underscored by the high levels of circulating microparticles in cGvHD patients which might explain the thrombophilic state in these patients.
Collapse
Affiliation(s)
- R Pihusch
- Medizinische Klinik III - Grobetahadern, Klinikum der Ludwig Maximilians-Universität München, Germany
| | | | | | | | | | | | | |
Collapse
|
35
|
Pihusch R, Höhnberg B, Salat C, Pihusch M, Hiller E, Kolb HJ. Platelet flow cytometric findings in patients undergoing conditioning therapy for allogeneic hematopoietic stem cell transplantation. Ann Hematol 2002; 81:454-61. [PMID: 12224003 DOI: 10.1007/s00277-002-0494-z] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2002] [Accepted: 06/03/2002] [Indexed: 10/27/2022]
Abstract
The conditioning regimen preceding hematopoietic stem cell transplantation (HSCT) causes a rapid decrease in the platelet count and signs of disseminated intravascular coagulation, possibly indicating platelet activation. As impacts during the conditioning regimen may predict later transplantation-associated complications, we investigated changes in platelet membrane glycoproteins (GP) and the liberation of microparticles. Platelet receptors and granules of 49 patients undergoing HSCT were evaluated by flow cytometric analysis before and after the different phases of the conditioning regimen [chemotherapy, total body irradiation (TBI), therapy with antithymocyte globulin (ATG)] and final transplantation. Following chemotherapy a high surface expression of CD62P, a low mepacrine staining, and a reduced surface expression of CD42b (part of the GP Ib/V/IX complex) were found, indicating an irreversible activation of platelets. In addition, elevated levels of circulating microparticles were observed, which may reinforce the thrombosis risk in these patients. Treatment with ATG leads to an elevated surface expression of PAC-1 epitopes, which are neoepitopes appearing after activation of GP IIb/IIIa. However, a significant degranulation was not detectable, which may be the consequence of inhibitory influences on platelets during ATG-induced cytokine release syndrome. TBI and transplantation itself had no influence on platelets. This study was able to demonstrate activating effects on platelets by certain phases of the conditioning regimen in patients receiving HSCT. Chemotherapy, in particular, leads to a strong and irreversible platelet activation and a generation of microparticles, which may cause an increased thrombosis risk. Our findings underline the impact of platelets on the pathogenesis of hemostatic complications during HSCT.
Collapse
Affiliation(s)
- R Pihusch
- Medizinische Klinik III-Grosshadern, Klinikum der Ludwig-Maximilians-Universität, Marchioninistr. 15, 81377 München, Germany.
| | | | | | | | | | | |
Collapse
|
36
|
Schoberth A, Prang N, Menzel H, Janni W, Braun S, Salat C, Heiss M, Kolb HJ, Lindhofer H. A new class of trifunctional bispecific antibodies mediated efficient immunological purging of peripheral blood stem cells. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)80414-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
37
|
Munker R, Salat C, Pihusch R, Diem H, Hiller E, Glass J, Kolb HJ, Yu H. Levels of insulin-like growth factor after stem cell transplantation. Eur J Med Res 2001; 6:181-4. [PMID: 11309231] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023] Open
Abstract
Some cytokines, i.e. tumor necrosis factor-, interleukin-6 and soluble interleukin-2 receptors are associated with complications of stem cell transplantation. Insulin-like growth factors (IGFs) are a family of peptides essential for the proliferation of normal and malignant cells. Recently increased levels of IGFs have been associated with the development of malignant tumors. In this communication we report on 96 measurements of insulin-like growth factor-I (IGF-1), insulin-like growth factor-II (IGF-2), and insulin-like growth factor-binding protein-3 (IGFBP-3) performed in 19 patients following stem cell transplants. Seventeen patients had allogeneic and 2 patients autologous transplants. Most IGF determinations were made at days 0, 7, 14, 21 and 28, some at other time points. The baseline values (day 0) of IGF-1 and IGFBP-3 were not different from controls. IGF-2 values were slightly lower than controls. Following transplantation, a consistent increase of IGF-1 was observed in 9/16 patients at days 7 and 14. Later the values decreased again. IGF-2 and IGFBP-3 did not change significantly after transplantation. No direct correlation could be established with the severity of graft-versus-host disease, levels of interleukin-6 and the time to hematopoietic recovery. A potential relevance of IGFs following stem cell transplantation may be the early diagnosis of liver damage and the development of second malignancies. More studies are necessary to investigate the pathophysiology and the clinical relevance of the increase of IGF-1 following stem cell transplantation.
Collapse
Affiliation(s)
- R Munker
- Städt. Krankenhaus München Harlaching, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
38
|
Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, Neumeister P, Finazzi G, Iacobelli M, Bowyer K, Prentice HG, Barbui T. Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000; 111:1122-9. [PMID: 11167751 DOI: 10.1046/j.1365-2141.2000.02475.x] [Citation(s) in RCA: 144] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Severe hepatic veno-occlusive disease (VOD) is a recognized complication of autologous and allogeneic stem cell transplantation (SCT) that is often fatal. Defibrotide (DF) is a polydeoxyribonucleotide that has been found to have anti-thrombotic, anti-ischaemic and thrombolytic properties without causing significant anticoagulation. Preliminary studies have demonstrated activity for DF in the treatment of VOD, with minimal associated toxicity. In the present study, 40 patients who fulfilled established criteria for VOD were treated with DF on compassionate grounds in 19 European centres; 28 patients met risk criteria predicting progression of VOD and fatality or had evidence of multiorgan failure (MOF), and were defined as 'poor-risk'. DF was commenced intravenously at a median of 14 d (range, -2 d to 53 d) post SCT at doses ranging from 10 to 40 mg/kg. The median duration of therapy was 18 d (range, 2--71 d). Twenty-two patients showed a complete response (CR) (bilirubin < 34.2 micromol/l and resolution of signs/symptoms of VOD and end-organ dysfunction) [CR = 55%, confidence interval (CI) 40--70%] and 17 patients (43%) are alive beyond d +100. Ten poor-risk patients showed a complete response (CR = 36%, CI 21--51%). These results demonstrate that DF is an active treatment for VOD following SCT and a randomized trial is now underway in order to further evaluate its role.
Collapse
Affiliation(s)
- R Chopra
- Department of Medical Oncology, Christie Hospital, Wilmslow Road, Manchester, UK.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Issels R, Abdel-Rahman S, Falk M, Salat C, Ochmann O, Reiser M, Hiddemann W. Initial response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) in high-risk soft tissue sarcomas (HR-STS) of adults and its correlation to survival parameters. Eur J Cancer 1999. [DOI: 10.1016/s0959-8049(99)81481-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
40
|
Falk M, Salat C, Mempel W, Kolb H, Theiss F, Schneller F, Peschel C, Rommel F, Hiddemann W, Issels R. Toxicity profile of a high-dose (HD) chemotherapy regimen with peripheral blood stem cell rescue (PBSCR) for adults with soft tissue sarcoma (STS). Eur J Cancer 1999. [DOI: 10.1016/s0959-8049(99)81501-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
41
|
Salat C, Holler E, Hiller E, Pihusch R, Kolb HJ. Hepatic veno-occlusive disease following peripheral blood stem cell or bone marrow transplantation. Haematologica 1999; 84 Suppl EHA-4:40-3. [PMID: 10907464] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/17/2023] Open
Affiliation(s)
- C Salat
- Medical Department III, Klinikum Grosshadern, Ludwig-Maximilians-Universität München, Germany.
| | | | | | | | | |
Collapse
|
42
|
Salat C. [D-dimer determination in acute thromboses]. Internist (Berl) 1999; 40:565. [PMID: 10407767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
Affiliation(s)
- C Salat
- Medizinische Klinik III, Klinikum Grosshadern der Ludwig-Maximilians-Universität, München
| |
Collapse
|
43
|
Salat C, Holler E, Kolb HJ, Pihusch R, Reinhardt B, Penovici M, Ledderose G, Hiller E. The relevance of plasminogen activator inhibitor 1 (PAI-1) as a marker for the diagnosis of hepatic veno-occlusive disease in patients after bone marrow transplantation. Leuk Lymphoma 1999; 33:25-32. [PMID: 10194118 DOI: 10.3109/10428199909093722] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Hepatic veno-occlusive disease (VOD) is the third most important fatal complication in allogeneic bone marrow transplantation (BMT), the second most significant one in the autologous setting and the most severe of all the regimen related toxicities. A growing number of VOD cases has to be expected due to the increasing number of high dose chemotherapies given with consecutive stem cell transplantation in patients with solid tumors. Confirmation of the diagnosis of VOD by biopsy is associated with a high risk of severe bleeding complications and, unfortunately, until now reliable laboratory markers have not as yet been established. Recently, plasminogen activator inhibitor 1 (PAI-1), the main inhibitor of the fibrinolytic system, has been found to be significantly elevated in VOD patients probably reflecting hypofibrinolysis in these patients. Furthermore, PAI-1 was able to distinguish between patients with VOD and those with hyperbilirubinemia after BMT caused by graft-versus-host-disease (GVHD) or toxic effects, in which cases the PAI-1 levels were mostly within the normal range. In this overview we summarize the data strongly indicating that PAI-1 is a useful marker for the diagnosis of VOD and helps in the differential diagnosis of hyperbilirubinemia after BMT.
Collapse
Affiliation(s)
- C Salat
- Department of Hematology, Med. Klinik III Klinikum Grosshadern, Munich, Germany
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Neumeister P, Hiller E, Gawaz M, Holler E, Kolb HJ, Sill H, Pihusch R, Mempel W, Wittmann G, Salat C. Changes in platelet membrane glycoproteins before bone marrow transplantation and after engraftment--a pilot study. Eur J Med Res 1998; 3:465-9. [PMID: 9753703] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023] Open
Abstract
Thrombotic complications are observed in patients undergoing bone marrow transplantation despite thrombocytopenia and impaired coagulation due to liver function disturbances. Endothelial cell damage which is involved in the pathogenesis of major transplant related complications like graft-versus-host disease, veno-occlusive disease, sepsis or microangiopathy may be a contributing factor. Little is known about platelet function in bone marrow transplant recipients. In order to study functional alterations in circulating platelets we investigated unstimulated and ADP-stimulated platelets of 10 bone marrow transplant recipients ex vivo by flow cytometry in a pilot study using a panel of monoclonal antibodies to characterize changes in membrane glycoproteins. Samples were collected before and during conditioning and at three timepoints after engraftment. 10 healthy volunteers served as controls. Platelets of bone marrow transplant recipients showed partly a significant, higher expression of surface bound fibrinogen, activated fibrinogen receptor, and glycoprotein Ib as compared to controls. P-selectin, a marker of platelet degranulation was significantly elevated after ADP-induced stimulation at all timepoints compared to controls. Only marginal differences were found for GP IIb/IIIa surface expression. The data point to an increased platelet activation state in bone marrow transplant recipients which might contribute to the thrombotic phenomena observed in these patients.
Collapse
Affiliation(s)
- P Neumeister
- Division of Haematology, Department of Internal Medicine, Karl-Franzens-University Graz, Auenbruggerpl. 38, A-8036 Graz, Austria.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Salat C, Holler E, Kolb HJ, Pihusch R, Reinhardt B, Hiller E. Endothelial cell markers in bone marrow transplant recipients with and without acute graft-versus-host disease. Bone Marrow Transplant 1997; 19:909-14. [PMID: 9156265 DOI: 10.1038/sj.bmt.1700767] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
To investigate endothelial cell alterations in BMT recipients developing acute graft-versus-host disease (aGVHD) we determined levels of the endothelial cell markers von Willebrand factor (VWF) and thrombomodulin (TM) in 57 patients undergoing BMT. Before conditioning VWF and TM levels did not differ significantly between transplant recipients who later developed no or mild (grade I) aGVHD (group A, allogeneic n = 22, autologous n = 7; VWF 136.0 +/- 44.1%; TM 29.5 +/- 18.0 ng/ml), and those with moderate or severe (grade II or III) aGVHD (group B, n = 28; VWF 142.2 +/- 37.6%; TM 35.2 +/- 20.1 ng/ml). A first significant rise of both VWF and TM level was noted after conditioning (day 0) both in group A (VWF 197.0 +/- 113.3%; P < 0.001; TM 39.3 +/- 23.3 ng/ml; P < 0.01) as well as in group B (VWF 201.7 +/- 53.3%; P < 0.0001; TM 43.5 +/- 23.5 ng/ml; P < 0.05). Subgroup analysis of autografted patients revealed no significant increase after conditioning in these patients. At the time of engraftment and onset of aGVHD (day 21), when VWF and TM levels within the groups were significantly elevated as compared with baseline (day -8) levels, group B patients (62.7 +/- 38.5 ng/ml) had significantly higher (P < 0.01) TM levels than patients of group A (37.4 +/- 19.6 ng/ml). This significant elevation also persisted at the end of the investigational period (day 28; group B: 56.0 +/- 37.6 ng/ml; group A: 38.2 +/- 23.7 ng/ml; P < 0.01). An elevation of endothelial cell markers is found in the course of BMT, particularly after conditioning and at the time of engraftment. This increase is pronounced in patients with aGVHD suggesting not only epithelial cell but also endothelial cell injury during aGVHD.
Collapse
Affiliation(s)
- C Salat
- Med. Klinik III Klinikum Grosshadern, Munich, Germany
| | | | | | | | | | | |
Collapse
|
46
|
Salat C, Holler E, Kolb HJ, Reinhardt B, Pihusch R, Wilmanns W, Hiller E. Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplantation. Blood 1997; 89:2184-8. [PMID: 9058743] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023] Open
Abstract
Hepatic veno-occlusive disease (VOD) is a frequent and severe complication after bone marrow transplantation (BMT). We previously have described plasminogen activator inhibitor-1 (PAI-1) as a possible marker of VOD. To confirm the significance of this finding, we now determined PAI-1 levels in 31 of 186 consecutive patients undergoing BMT who developed hyperbilirubinemia greater than 3 mg/dL for various reasons. Diagnoses were made by clinical criteria and confirmed by biopsy in 23 of 31 patients. They included VOD (n = 7), acute graft-versus-host disease (GVHD) of the liver (n = 7), and other hepatic injury (n = 17). PAI-1 (mean +/- SD) was significantly (P < .001) elevated in patients with VOD (321.6 +/- 161.2 ng/mL) as compared with patients with GVHD (22.8 +/- 8.4 ng/mL) or other hepatic damage (32.8 +/- 30.8 ng/mL) at the timepoint of bilirubin increase. At the peak bilirubin concentration, the corresponding PAI-1 levels were 426.1 +/- 230.0 ng/mL in patients with VOD, 41.0 +/- 20.6 ng/ mL in patients with GVHD, and 44.6 +/- 32.9 ng/mL in patients with other hepatic injury (P < .001 VOD v GVHD/other hepatic injury). Our results underline the relevance of PAI-1 in the differential diagnosis of hyperbilirubinemia after BMT and its significance as a sensitive and specific marker of severe VOD.
Collapse
Affiliation(s)
- C Salat
- Medical Klinik III Klinikum Grosshadern der Ludwig-Maximilians-Universitat München, Germany
| | | | | | | | | | | | | |
Collapse
|
47
|
Salat C, Holler E, Wolf C, Kolb HJ, Reinhardt B, Pihusch R, Krämling HJ, Heinemann V, Haller M, Hiller E. Laboratory markers of veno-occlusive disease in the course of bone marrow and subsequent liver transplantation. Bone Marrow Transplant 1997; 19:487-90. [PMID: 9052916 DOI: 10.1038/sj.bmt.1700689] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Plasminogen activator inhibitor 1 (PAI-1) and amino-propeptide of type III procollagen (PIIINP) have been described as markers of hepatic veno-occlusive disease (VOD) after bone marrow transplantation (BMT). We determined these parameters in two patients undergoing BMT and subsequent liver transplantation due to VOD. Previously normal PAI-1 levels (maximum 30.0 ng/ml in patient 1, 23.7 ng/ml in patient 2) were elevated for the first time in both patients at the time of clinically diagnosed VOD on days 40 and 20, respectively (patient 1: 317.5 ng/ml; patient 2: 317.2 ng/ml). Levels remained elevated until liver transplantation was performed on days 79 and 41, respectively. Baseline levels (day -8) of aminopropeptide of type III collagen (patient 1: 4.44 microg/l; patient 2: 8.1 microg/l) peaked at the time of BMT in both patients (155.0 microg/l and 108.3 microg/l). After an intermittent decrease at the time of discharge on day 32, a second elevation was observed in patient 1 when she was readmitted and presented with typical signs of VOD on day 40. In patient 2, PIIINP levels remained high until VOD was diagnosed (day 20) and liver transplantation was performed. After liver transplantation, PAI-1 levels normalized in both patients and PIIINP levels declined. Both patients died due to infectious complications and multiorgan failure on days 141 and 101, respectively. Whereas the early rise of PIIINP did not correlate with the clinical onset of VOD, the results emphasise the relevance of PAI-1 for diagnosing VOD.
Collapse
Affiliation(s)
- C Salat
- Med. Klinik III Klinikum Grosshadern, Ludwig-Maximilians-Universitat Munchen, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Salat C, Holler E, Göhring P, Poley S, Kolb HJ, Pihusch R, Reinhardt B, Krämling HJ, Haller M, Hiller E. Protein C, protein S and antithrombin III levels in the course of bone marrow and subsequent liver transplantation due to veno-occlusive disease. Eur J Med Res 1996; 1:571-4. [PMID: 9438165] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
Veno-occlusive disease (VOD) of the liver is one of the most frequent fatal complications after bone marrow transplantation (BMT). A decrease of natural anticoagulants, in particular protein C (PC), has been assumed to be involved in the pathogenesis of the disease. We determined PC and antithrombin III (AT III) levels in two patients undergoing BMT and subsequent liver transplantation due to VOD. Additionally, in one of the patients protein S (PS) levels were also measured. Normal baseline (day-8) PC levels (86 and 89%) were markedly reduced in both patients at the time of VOD manifestation on day 20 and 40, respectively (26 and 31%). PS levels lay within the normal range from day-8 (before myeloablative chemotherapy) until one week after clinical onset of VOD when substitution therapy with fresh frozen plasma (FFP) was initiated. AT III levels decreased moderately during the second and third posttransplant week, but were normal in the patient with a late clinical manifestation of VOD. In both patients PC and PS levels lay within the normal range after liver transplantation which was performed on day 41 and 79, respectively. AT III was substituted several times. Both patients died due to infectious complications on day 141 and 101, respectively. The data confirm previous reports that a decrease of PC is observed in BMT recipients and can be associated with hepatic vein occlusion. Whereas the relevance of AT III is uncertain, PS does not seem to be involved in the pathogenesis of VOD. Liver transplantation lead to normalization of PC levels, but its significance remains to be discussed in terms of ethical justifiability, medical feasibility and costs.
Collapse
Affiliation(s)
- C Salat
- Med. Klinik III, Klinikum Grosshadern, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Pihusch R, de Coutre P, Salat C, Göhring P, Poley S, Hiller E. [19-year-old patient with thromboembolism caused by oral contraception]. Internist (Berl) 1996; 37:1163-6. [PMID: 9036113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- R Pihusch
- Medizinische Klinik III, Klinikum Grosshadern, Ludwig-Maximilians-Universität München
| | | | | | | | | | | |
Collapse
|
50
|
Salat C, Boekstegers P, Holler E, Werdan K, Reinhardt B, Fateh-Moghadam S, Pihusch R, Kaul M, Beinert T, Hiller E. Hemostatic parameters in sepsis patients treated with anti-TNF alpha-monoclonal antibodies. Shock 1996; 6:233-7. [PMID: 8902937 DOI: 10.1097/00024382-199610000-00001] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Tumor necrosis factor-alpha (TNF alpha) is a central mediator in the pathogenesis of sepsis. It also interferes with the hemostatic system and exerts and a net procoagulant effect. Since TNF alpha may contribute to thrombotic complications in sepsis patients, we determined markers of thrombin activation, parameters of the fibrinolytic system (D-dimer, tissue plasminogen activator antigen (tPA) urinary type plasminogen activator antigen (uPA), plasminogen activator inhibitor antigen (PAI-1) and von Willebrand factor antigen (vWF) in 30 patients with sepsis or septic shock. All patients were treated with standard therapy, but 14 patients were treated additionally with an anti-TNF alpha monoclonal antibody (MAK 195F); 16 patients served as historical controls. No significant effect of the antibody on the parameters of the hemostatic system could be determined. Our data speak against a modulation of coagulation or the fibrinolytic system by the monoclonal anti-TNF alpha antibody MAK 195F in this cohort of sepsis patients.
Collapse
Affiliation(s)
- C Salat
- Department of Internal Medicine III, Klinikum Grosshadern, Ludwig-Maximilians-Universität, Munich, Germany
| | | | | | | | | | | | | | | | | | | |
Collapse
|